

Special Issue

Cancer Immunotherapy: Current Advancements and Future Perspectives

Message from the Guest Editors

The goal of immune therapy is to elicit and maintain an immune mediation response to cancer cells to establish a self-sustained process. This approach demonstrates its significant effectiveness in diseases where therapeutic options are not particularly effective.

Unfortunately, the percentage of patients who benefit from these treatments remains limited. Regarding radiotherapy, it is well-known that it can induce abscopal and bystander effects by recruiting immune cells against the tumor. Unfortunately, such responses are episodic and not systematically inducible. These may be synergized and promoted by immunotherapy. Bench-to-bedside and vice versa findings are welcome in this Special Issue to shed light on the rationale and mechanisms of these new therapeutic opportunities. The weapon of immunotherapy should be made effective for a larger number of patients. It is also important to effectively combine immunotherapy with chemotherapy, radiotherapy or targeted therapies aiming towards a complete and sustainable disease eradication.

Guest Editors

Dr. Stefano Forte

Istituto Oncologico del Mediterraneo, 95029 Viagrande, Italy

Dr. Gianluca Ferini

REM Radioterapia, 95029 Viagrande, Italy

Deadline for manuscript submissions

31 December 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/154779

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).